FY19 ended on a high as robust growth in the core portfolio outweighed the ongoing generic erosion in off-patent drugs. The mid-term top-line outlook appears strong on the back of a renewed R&D pipeline; however, profitability could come under pressure due to higher investments into R&D and commercial infrastructure (particularly for Eptinezumab). The recent outbreak of Coronavirus is also a near-term risk.
19 Feb 2020
Strong finish to FY19
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong finish to FY19
H. Lundbeck A/S Class B (LUNB:WBO) | 0 0 0.0%
- Published:
19 Feb 2020 -
Author:
Rishabh Kochar -
Pages:
3
FY19 ended on a high as robust growth in the core portfolio outweighed the ongoing generic erosion in off-patent drugs. The mid-term top-line outlook appears strong on the back of a renewed R&D pipeline; however, profitability could come under pressure due to higher investments into R&D and commercial infrastructure (particularly for Eptinezumab). The recent outbreak of Coronavirus is also a near-term risk.